Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7966 to 7980 of 8907 results

  1. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Withdrawn guidance

  2. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Withdrawn guidance

  3. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Withdrawn guidance

  4. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

    Withdrawn guidance

  5. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Withdrawn guidance

  6. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  7. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Withdrawn guidance

  8. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

    Withdrawn guidance

  9. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Withdrawn guidance

  10. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Withdrawn guidance

  11. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  12. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  13. Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255)

    This guidance has been updated and replaced by NICE technology appraisal guidance 391.

    Withdrawn guidance

  14. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Withdrawn guidance

  15. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance